Exkivity has been withdrawn from the U.S. market. In clinical studies, close to 28% of patients had a partial response (tumor shrinkage) to Exkivity treatment for Exon 20 mutations and the response lasted for about 17.5 months. About 40% of participants had a response to single agent Rybr...